IL-17A upregulates keratin 17 expression in keratinocytes through STAT1-and STAT3-dependent mechanisms

Journal of Investigative Dermatology

Volumn 131, Issue 12, 2011, Pages 2401-2408

  Shi, Xiaowei ^a,b   Jin, Liang ^a   Dang, Erle ^a   Chang, Ting ^a   Feng, Zhenzhen ^a   Liu, Yufeng ^a   Wang, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b The 210th Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKERATIN 17; FLUDARABINE; INTERLEUKIN 17; MESSENGER RNA; PICEATANNOL; PYRROLIDINE DITHIOCARBAMATE; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EPIDERMIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 80855148155     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.222     Document Type: Article

References (38)

1. Albanesi C, Cavani A, Girolomoni G (1999) IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 162:494-502 (Pubitemid 29018959)
2. Albanesi C, Scarponi C, Cavani A et al. (2000) Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma-and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 115:81-7 (Pubitemid 30470196)
3. Arican O, Aral M, Sasmaz S et al. (2005) Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273-9 (Pubitemid 41577417)
4. Bockelmann R, Horn T, Gollnick H et al. (2005) Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco-and gene-therapeutic effects. Skin Pharmacol Physiol 18:42-54 (Pubitemid 40082228)
5. Bonnekoh B, Huerkamp C, Wevers A et al. (1995) Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-gamma. J Invest Dermatol 104:58-61
6. Caproni M, Antiga E, Melani L et al. (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:210-4
7. Depianto D, Kerns ML, Dlugosz AA et al. (2010) Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet 42:910-4
8. de Jong EM, van Vlijmen IM, van Erp PE et al. (1991) Keratin 17: a useful marker in anti-psoriatic therapies. Arch Dermatol Res 283:480-2
9. Fitch E, Harper E, Skorcheva I et al. (2007) Pathology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9:461-7 (Pubitemid 350305203)
10. Fierlbeck G, Rassner G, Muller C (1990) Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 126:351-5 (Pubitemid 20094675)
11. Gaffen SL (2008) An overview of IL-17 function and signaling. Cytokine 43:402-7
12. Harrington LE, Hatton RD, Mangan PR et al. (2005) Interleukin-17- producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-32 (Pubitemid 41541790)
13. Ivanov S, Lindén A (2007) Th-17 cells in the lungs? Exp. Rev Resp Med 1:279-93
14. Ivanov S, Lindén A (2009) Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 30:95-103
15. Jiang CK, Flanagan S, Ohtsuki M et al. (1994) Disease-activated transcription factor: allergic reactions in human skin cause nuclear translocation of STAT-91 and induce synthesis of keratin K17. Mol Cell Biol 14:4759-69 (Pubitemid 24196826)
16. Johansen C, Kragballe K, Westergaard M et al. (2005) The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 152:37-42
17. Kagami S, Rizzo HL, Lee JJ et al. (2010) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130:1373-83
18. Kolls JK, Lindén A (2004) Interleukin-17 family members and inflammation. Immunity 21:467-76 (Pubitemid 39370503)
19. Komine M, Freedberg IM, Blumenberg M (1996) Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. J Invest Dermatol 107:569-75 (Pubitemid 26338581)
20. Ksatelan M, Massari LP, Pasic A et al. (2004) New trends in the immunopathogenesis of psoriasis. Acta Dermatovenerol Croat 12:26-9 (Pubitemid 38524294)
21. Lee FEH, Georas SN, Beck LA (2010) IL-17: Important for host defense, autoimmunity, and allergy? J Invest Dermatol 130:2540-2
22. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207-11 (Pubitemid 351543220)
23. McFadden JP, Baker BS, Powles AV et al. (2009) Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 160:929-37
24. Miyoshi K, Takaishi M, Nakajima K et al. (2011) Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 131:108-17
25. Murano M, Maemura K, Hirata I et al. (2000) Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 120:51-8 (Pubitemid 30176899)
26. Park H, Li Z, Yang XO et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133-41 (Pubitemid 41541791)
27. Shen F, Gaffen SL (2008) Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 41:92-104
28. Shen Z, Chen L, Liu YF et al. (2006) Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis. J Am Acad Dermatol 54:992-1002
29. Shen Z, Wang G, Fan JY et al. (2005) HLA DR B1*04, *07-restricted epitopes on keratin 17 for autoreactive T cells in psoriasis. J Dermatol Sci 38:25-39 (Pubitemid 40410628)
30. Sigmundsdottir H, Sigurgeirsson B, Troye-Blomberg M et al. (1997) Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45:688-97 (Pubitemid 27250239)
31. Subramaniam SV, Cooper RS, Adunyah SE (1999) Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem Biophys Res Commun 262:14-9 (Pubitemid 29412615)
32. Teunissen MB, Koomen CW, de Waal MR et al. (1998) Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111:645-9 (Pubitemid 28452327)
33. Valdimarsson H, Sigmundsdottir H, Jonsdottir I (1997) Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin ? Clin Exp Immunol 107(Suppl):21-4 (Pubitemid 27019967)
34. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al. (2009) Psoriasis-as an autoimmune disease caused by molecular mimicry. Trends Immunol 30:494-501
35. Van Beelen AJ, Teunissen MBM, Kapsenberg ML et al. (2007) Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 7:374-81 (Pubitemid 47415279)
36. Weaver CT, Harrington LE, Mangan PR et al. (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677-88 (Pubitemid 43867371)
37. Weaver CT, Hatton RD, Mangan PR et al. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25:821-52 (Pubitemid 46697925)
38. Wynn TA (2005) Th-17: a giant step from Th-1 and Th-2. Nat Immunol 6:1069-70